Lumicef

Lumicef

brodalumab

Manufacturer:

Kyowa Kirin

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Brodalumab
Indications/Uses
Psoriasis vulgaris in patients w/ inadequate response to phototherapies or other existing systemic therapies (except biologics) & those w/ skin eruptions over 10% or more of BSA; in patients w/ intractable skin eruptions.
Dosage/Direction for Use
SC Adult 1st dose 210 mg, followed by doses 1 wk later, 2 wk later, & once every 2 wk thereafter.
Contraindications
Hypersensitivity, serious infection, active TB.
Special Precautions
Infections or suspected infections; history of TB; depression or w/ such a history; history of suicidal ideation or attempt; active Crohn's disease; malignant tumors. Avoid live vaccines & other biologics. Pregnancy & lactation. Childn. Elderly.
Adverse Reactions
Serious infection, decreased neutrophil count, serious hypersensitivity.
MIMS Class
ATC Classification
L04AC12 - brodalumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Lumicef inj 210 mg/1.5 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in